Towards Imaging Biomarkers for Osteoarthritis: Surprises, Challenges, and Opportunities
Add an upcoming event to your calendar.
Biomarker development requires two phases of validation. The first is technical validity: is the marker measuring what it aims to measure? The second it pathophysiologic validity: is the information provided by the marker of pathophysiological or clinical use? Many of the magnetic resonance imaging techniques that have been emerging over the past decades appear promising in that they have shown technical validity in measuring the morphologic and molecular state of cartilage, and with emerging clinical studies, efforts are beginning to offer evidence regarding pathophysiological validity. As a case study, this talk will focus on biomarkers for glycosaminoglycan (GAG). In addition to illustrating technical and pathophysiological validity, and some of the surprising insights that have come along the way, we will also explore the way in which such biomarkers might change the scientific and clinical paradigm for advancing our
The NIH Director's Wednesday Afternoon Lecture Series includes weekly scientific talks by some of the top researchers in the biomedical sciences worldwide.